Table 8.
Efficacy and potency of pure cannabinoids and of most of their corresponding ‘botanical drug substance’ (BDS) as inhibitors of human recombinant NAAA
| Compounds | IC50 (µM) | Max concentration tested (% inhibition) |
|---|---|---|
| CBC | >100 µM | 100 µM |
| 40.6 ± 2.1 | ||
| CBC-BDS | 14.2 ± 6.2 | 100 µM |
| 81.0 ± 5.1 | ||
| CBD | >100 µM | 100 µM |
| 47.2 ± 2.6 | ||
| CBD-BDS | >100 µM | 100 µM |
| 47.2 ± 3.4 | ||
| CBG | >100 µM | 100 µM |
| 19.4 ± 2.1 | ||
| CBG-BDS | 18.3 ± 9.4 | 100 µM |
| 68.5 ± 8.2 | ||
| CBN | >50 µM | 50 µM |
| 31.4 ± 2.9 | ||
| CBDA | 23.0 ± 1.3 | 50 µM |
| 62.5 ± 1.1 | ||
| CBDA-BDS | >50 µM | 50 µM |
| 43.8 ± 8.4 | ||
| CBGA | >50 µM | 50 µM |
| 33.2 ± 2.9 | ||
| CBDV | 72.3 ± 18.4 | 100 µM |
| 54.5 ± 6.1 | ||
| CBDV-BDS | >100 µM | 100 µM |
| 47.2 ± 8.2 | ||
| CBGV | >50 µM | 50 µM |
| 38.4 ± 4.0 | ||
| CBGV-BDS | 24.4 ± 2.1 | 100 µM |
| 75.0 ± 9.1 | ||
| THCA | >50 µM | 50 µM |
| 21.1 ± 1.8 | ||
| THCA-BDS | >50 µM | 50 µM |
| 25.5 ± 6.8 | ||
| THCV | >100 µM | 100 µM |
| 18.2 ± 9.1 | ||
| THCV-BDS | >100 µM | 100 µM |
| 21.4 ± 3.1 | ||
| THCVA | >100 µM | 100 µM |
| 20.5 ± 3.5 | ||
| THCVA-BDS | >100 µM | 100 µM |
| 44.7 ± 4.3 |
Data are means ± SEM of at least n = 3 separate experiments in which various concentrations (1, 10, 25, 50 or 100 µM) of the pure compounds/BDS were incubated. Efficacy was calculated as % of NAAA inhibition at the maximal concentration tested (which is shown in the first line of the cell).
CBC, cannabichromene; CBD, cannabidiol; CBDA, cannabidiol acid; CBDV, propyl analogue of CBD or cannabidivarin; CBG, cannabigerol; CBGV, cannabigivarin; CBN, cannabinol; NAAA, N-acylethanolamine acid amide hydrolase; THC, Δ9-tetrahydrocannabinol; THCA, THC acid; THCV, propyl analogue of THC or tetrahydrocannabivarin; THCVA, tetrahydrocannabivarin acid.